Program
briquilimab
Also written as “Briquilimab”, “Humanized anti-CD117 Monoclonal Antibody (JSP191)” and “JSP191”.
Its studies are mostly in Chronic Urticaria · Leukemia, Myeloid, Acute · Urticaria · Asthma · Immunologic Deficiency Syndromes, led by Jasper Therapeutics.
Furthest: phase 2, since Nov 2, 20167 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jasper Therapeutics | 70 open or running | phase 2since Nov 2, 2016 | Nov 2, 2016 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2016First study: phase 2 study in Immunologic Deficiency SyndromesFirst studyNCT02963064 · 23 enrolled · United States
- Jun 10, 2020Phase 1 study in Anemia, Refractory, with Excess of BlastsNCT04429191 · 32 enrolled · United States
- Jun 5, 2023Phase 1 study in CytopeniaNCT05903274 · 6 enrolled · United States
- Nov 21, 2023Phase 2 study in Chronic UrticariaNCT06162728 · 87 enrolled · United States, Germany
- Apr 3, 2024Phase 2 study in Chronic Inducible UrticariaNCT06353971 · 27 enrolled · Germany
- Sep 6, 2024Phase 1 study in AsthmaNCT06592768 · 17 enrolled · Canada
- Nov 20, 2024Phase 2 study in Chronic UrticariaNCT06736262 · 67 enrolled · United States, Germany
TargetBeta
KIT →read by rule
“A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs)”NCIt, by rule
“Stem cell growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on KIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| velzatinib | GlaxoSmithKline | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| elenestinib | Sanofi | phase 3 | 3 |
| NB-003rule | ningbo-newbay-technology-development-co-ltd | phase 3 | 2 |
| BLU-808 | Sanofi | phase 2 | 3 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06736262Chronic Urticaria · United States, Germany | 2 | Terminated | Jul 21, 2026 | 67 |
| NCT06592768Asthma · Canada | 1 | Terminated | Aug 11, 2025 | 17 |
| NCT06353971Chronic Inducible Urticaria · Germany | 2 | Terminated | Jul 31, 2025 | 27 |
| NCT06162728Chronic Urticaria · United States, Germany | 2 | Completed | Jul 8, 2026 | 87 |
| NCT05903274Cytopenia · United States | 1 | Terminated | Oct 21, 2024 | 6 |
| NCT04429191Anemia, Refractory, with Excess of Blasts · United States | 1 | Completed | Jun 13, 2023 | 32 |
| NCT02963064Immunologic Deficiency Syndromes · United States | 2 | Terminated | Jul 7, 2025 | 23 |
How it is read
Names in the registry
- “Briquilimab”, 4 entries
- “Humanized anti-CD117 Monoclonal Antibody (JSP191)”, 2 entries
- “JSP191”, 1 entry
Conditions, from the studies’ own filings
- Chronic Urticaria, 2 studies
- Leukemia, Myeloid, Acute, 1 study
- Urticaria, 1 study
- Asthma, 1 study
- Immunologic Deficiency Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.